Efficacy and Safety of Mistletoe Preparations (Viscum album) for Patients with Cancer Diseases
A Systematic ReviewMelzer J. · Iten F. · Hostanska K. · Saller R.
Institute of Complementary Medicine, Department of Internal Medicine, University Hospital Zurich, Switzerland
Background: Mistletoe is often used as a complementary approach in oncology. Despite experimental anti-tumour effects and several reviews there remains controversy about its clinical role. Patients and Methods: Potentially relevant trials were identified to perform a systematic review (databases: e.g. EMBASE, MEDLINE; hand search: e.g. bibliographies; search terms: e.g. mistletoe). To be included, randomised or comparative clinical trials at least had to examine mistletoe preparations standardized according to manufacturing process and to describe interventions explicitly. Additionally, cohort studies were included for reasons of external validity. Results were summarised in tables. Results: 18 clinical trials (>6,800 participants) were included. Their internal quality was mostly low. Due to heterogeneity between trials a meta-analysis was impossible. Regarding efficacy, findings were inconsistent regarding life expectancy, relation to tumour entity, dosing and treatment duration. Yet, studies indicate that quality of life (QoL) is improved. As these findings do not seem to be limited to one of the different parenteral mistletoe preparations reviewed the treatment may be summarised under the umbrella term ‘mistletoe therapy’. Regarding safety, 1 serious adverse event (AE) related to mistletoe was described; non-serious AEs were local reactions at injection site. Allergic reactions were rare. Conclusion: Supportive ‘mistletoe therapy’ seems safe and beneficial for QoL in adult patients with solid tumours. But there is an urgent need to confirm its efficacy in patient-centred care in a complex oncological setting. This has to be evaluated systematically in prospective observational trials with validated, multidimensional patient-rated QoL questionnaires and comparisons of different preparations and dosages.
Jörg Melzer, MD Institute of Complementary Medicine, Department of Internal Medicine University Hospital Zurich CH-8091 Zurich, Switzerland Tel. +41 44 255-2460, Fax -4394 email@example.com
Published_online: July 17, 2009
Number of Print Pages : 10
Additional supplementary material is available online - Number of Parts : 1
Forschende Komplementärmedizin / Research in Complementary Medicine (Research Practice Perspectives - Wissenschaft Praxis Perspektiven)
Vol. 16, No. 4, Year 2009 (Cover Date: September 2009)
Journal Editor: Walach H. (Northampton)
ISSN: 1661-4119 (Print), eISSN: 1661-4127 (Online)
For additional information: http://www.karger.com/FOK